In this episode of Life Science Lab, host Christopher Conway, Chief Philanthropy Officer and Executive Vice President of Strategic Communications at the Indiana Biosciences Research Institute (IBRI), talks with Ramani Varanasi, CEO of Libris Innovations, the for-profit subsidiary of the IBRI. They discuss how IBRI's research engine and Libris Innovations' venture creation efforts work hand in hand to advance scientific discoveries toward commercialization and patient impact. Ramani also shares her perspective on the biotech investment climate, Indianapolis' growing life sciences ecosystem, and her early priorities for Libris Innovations.

About Libris Innovations

Libris Innovations is the for-profit subsidiary of the Indiana Biosciences Research Institute, created to advance IBRI's most promising scientific discoveries into new life sciences companies dedicated to delivering medical innovations for patients in need. Libris oversees the formation and growth of ventures originating from IBRI and partner innovation, providing strategic guidance and advisory support to help early-stage biotechnology companies attract the capital, talent, and resources needed to succeed. Companies supported by Libris benefit from strategic direction and operational support that help move discoveries from research through development and commercialization.

Learn more about Libris Innovations here: https://www.indianabiosciences.org/libris-innovations/

About the Indiana Biosciences Research Institute

The Indiana Biosciences Research Institute (IBRI) is a first-in-class translational medicine institute dedicated to advancing life sciences in the race to eliminate disease and improve human health and life. By connecting early-stage biotech companies with cutting-edge life science discoveries —and backed by the mission and resources of industry leaders, investors, and philanthropic partners— IBRI is successfully evolving a new, independent model to conquer disease, uniting previously fragmented forces in the quest for cures.

Learn more about the IBRI here: https://www.indianabiosciences.org/

In the first episode of Life Science Lab, host Ari Landon, PhD sits down with Alan Palkowitz, PhD, President and CEO of the Indiana Biosciences Research Institute (IBRI), to discuss how the IBRI is accelerating translational research and advancing new therapies through collaboration across the life sciences ecosystem. They explore what makes the IBRI model unique, the institute's scientific priorities, and what it takes to move discoveries toward real-world impact.

About the Indiana Biosciences Research Institute

The Indiana Biosciences Research Institute (IBRI) is a first-in-class translational medicine institute dedicated to advancing life sciences in the race to eliminate disease and improve human health and life. By connecting early-stage biotech companies with cutting-edge life science discoveries —and backed by the mission and resources of industry leaders, investors, and philanthropic partners— IBRI is successfully evolving a new, independent model to conquer disease, uniting previously fragmented forces in the quest for cures.

Learn more about the IBRI here: https://www.indianabiosciences.org/